{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:13:46Z","timestamp":1790878426820,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41440-020-0531-0","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T08:45:59Z","timestamp":1597135559000},"page":"1141-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Recent advances in the management of pheochromocytoma and paraganglioma"],"prefix":"10.1038","volume":"43","author":[{"given":"Akiyo","family":"Tanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhide","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"531_CR1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"JW Lenders","year":"2005","unstructured":"Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665\u201375.","journal-title":"Lancet"},{"key":"531_CR2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2012-3020","volume":"98","author":"A Scholten","year":"2013","unstructured":"Scholten A, Cisco RM, Vriens MR, Cohen JK, Mitmaker EJ, Liu C, et al. Pheochromocytoma crisis is not a surgical emergency. J Clin Endocrinol Metab. 2013;98:581\u201391.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","volume":"51","author":"AMA Berends","year":"2018","unstructured":"Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, et al. Incidence of Pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med. 2018;51:68\u201373.","journal-title":"Eur J Intern Med"},{"key":"531_CR4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.0954-6820.1986.tb02755.x","volume":"220","author":"G Stenstrom","year":"1986","unstructured":"Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand. 1986;220:225\u201332.","journal-title":"Acta Med Scand"},{"key":"531_CR5","first-page":"378","volume":"113","author":"M Naruse","year":"2012","unstructured":"Naruse M, Tsuiki M, Nanba K, Nakao K, Tagami T, Tanabe A. [Etiology and clinical guidelines for the diagnosis and treatment of pheochromocytoma in Japan]. Nihon Geka Gakkai Zasshi. 2012;113:378\u201383.","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"531_CR6","doi-asserted-by":"crossref","unstructured":"Naruse M, PHEO-J Study Group. 2011 Nationwide survey and PHEO network for the study of pheochromocytoma\/paraganglioma in Japan (PHEO-J). Endocr Rev.2011; 32 Meeting Abstracts: P2\u2013631 (abstract 102).","DOI":"10.1210\/endo-meetings.2011.PART3.P10.P2-631"},{"key":"531_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, et al. Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21:405\u201314.","journal-title":"Endocr Relat Cancer."},{"key":"531_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1507\/endocrj.EJ18-0486","volume":"67","author":"T Ichijo","year":"2020","unstructured":"Ichijo T, Ueshiba H, Nawata H, Yanase T. A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J. 2020;67:141\u201352.","journal-title":"Endocr J"},{"key":"531_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41440-017-0002-4","volume":"41","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Sone M, Taura D, Yamasaki T, Kojima K, Honda-Kohmo K, et al. Evaluation of quantitative parameters for distinguishing pheochromocytoma from other adrenal tumors. Hypertens Res. 2018;41:165\u201375.","journal-title":"Hypertens Res"},{"key":"531_CR10","first-page":"354","volume":"56","author":"MG Sutton","year":"1981","unstructured":"Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. 1981;56:354.","journal-title":"Mayo Clin Proc"},{"key":"531_CR11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","volume":"287","author":"JW Lenders","year":"2002","unstructured":"Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287:1427\u201334.","journal-title":"JAMA"},{"key":"531_CR12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","volume":"60","author":"G Eisenhofer","year":"2014","unstructured":"Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem. 2014;60:1486\u201399.","journal-title":"Clin Chem"},{"key":"531_CR13","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Endocrine Society. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR14","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1507\/endocrj.EJ19-0125","volume":"66","author":"K Takekoshi","year":"2019","unstructured":"Takekoshi K, Satoh F, Tanabe A, Okamoto T, Ichihara A, Tsuiki M, et al. Correlation between urinary fractionated metanephrines in 24-hour and spot urine samples for evaluating the therapeutic effect of metyrosine: a subanalysis of a multicenter, open-label phase I\/II study. Endocr J. 2019;66:1063\u201372.","journal-title":"Endocr J"},{"key":"531_CR15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1507\/endocrj.EJ17-0276","volume":"65","author":"M Naruse","year":"2018","unstructured":"Naruse M, Satoh F, Tanabe A, Okamoto T, Ichihara A, Tsuiki M, et al. Efficacy and safety of metyrosine in pheochromocytoma\/paraganglioma: a multi-center trial in Japan. Endocr J. 2018;65:359\u201371.","journal-title":"Endocr J"},{"key":"531_CR16","first-page":"122","volume":"57","author":"V Rufini","year":"2013","unstructured":"Rufini V, Treglia G, Castaldi P, Perotti G, Giordano A. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review. Q J Nucl Med Mol Imaging. 2013;57:122\u201333.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"531_CR17","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"531_CR18","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","volume":"43","author":"I Janssen","year":"2016","unstructured":"Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, et al. PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43:1784\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"531_CR19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2214\/AJR.18.19881","volume":"211","author":"Y Sanli","year":"2018","unstructured":"Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, et al. Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET\/CT. Am J Roentgenol. 2018;211:267\u201377.","journal-title":"Am J Roentgenol"},{"key":"531_CR20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41440-019-0339-y","volume":"43","author":"M Parasiliti-Caprino","year":"2020","unstructured":"Parasiliti-Caprino M, Lucatello B, Lopez C, Burrello J, Maletta F, Mistrangelo M, et al. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertens Res. 2020;43:500\u201310.","journal-title":"Hypertens Res"},{"key":"531_CR21","unstructured":"Tischler AS, de Krijger RR, Gill AJ, Kawashima A, Kumura N, Komminoth P, et al. Phaechromocytoma. In: Loiyd R, Osamura R, Kloppel G, Juan R, editors. WHO classification of tumours of endocrine organs. 4th edn. Lyon: International Agency for Research on Cancer; 2017. p. 183\u201390."},{"key":"531_CR22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","volume":"26","author":"LD Thompson","year":"2002","unstructured":"Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26:551\u201366.","journal-title":"Am J Surg Pathol"},{"key":"531_CR23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, et al. Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21:405\u201314.","journal-title":"Endocr Relat Cancer"},{"key":"531_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12022-013-9269-4","volume":"24","author":"E Castelblanco","year":"2013","unstructured":"Castelblanco E, Santacana M, Valls J, de Cubas A, Casc\u00f3n A, Robledo M, et al. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas. Endocr Pathol. 2013;24:199\u2013205.","journal-title":"Endocr Pathol"},{"key":"531_CR25","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/modpathol.2015.41","volume":"28","author":"TG Papathomas","year":"2015","unstructured":"Papathomas TG, Oudijk L, Persu A, Gill AJ, van Nederveen F, Tischler AS, et al. SDHB\/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a multinational study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol. 2015;28:807\u201321.","journal-title":"Mod Pathol"},{"key":"531_CR26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2015","unstructured":"Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11:101\u201311.","journal-title":"Nat Rev Endocrinol"},{"key":"531_CR27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/cen.12530","volume":"82","author":"JP Brito","year":"2015","unstructured":"Brito JP, Asi N, Bancos I, Gionfriddo MR, Zeballos-Palacios CL, Leppin AL, et al. Testing for germline mutations in sporadic pheochromocytoma\/paraganglioma: a systematic review. Clin Endocrinol. 2015;82:338\u201345.","journal-title":"Clin Endocrinol"},{"key":"531_CR28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2016.01.022","volume":"100","author":"S Pillai","year":"2016","unstructured":"Pillai S, Gopalan V, Smith RA, Lam AK. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Crit Rev Oncol Hematol. 2016;100:190\u2013208.","journal-title":"Crit Rev Oncol Hematol"},{"key":"531_CR29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","volume":"1","author":"PL Dahia","year":"2005","unstructured":"Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005;1:72\u201380.","journal-title":"PLoS Genet."},{"key":"531_CR30","doi-asserted-by":"crossref","first-page":"E369","DOI":"10.1210\/jc.2013-2600","volume":"99","author":"A Buffet","year":"2014","unstructured":"Buffet A, Smati S, Mansuy L, M\u00e9nara M, Lebras M, Heymann MF, et al. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab. 2014;99:E369\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","volume":"55","author":"KA Andrews","year":"2018","unstructured":"Andrews KA, Ascher DB, Pires DEV, Barnes DR, Vialard L, Casey RT, et al. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD. J Med Genet. 2018;55:384\u201394.","journal-title":"J Med Genet"},{"key":"531_CR32","volume":"27","author":"LJ Castro-Vega","year":"2015","unstructured":"Castro-Vega LJ, Letouz\u00e9 E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015;27:6044.","journal-title":"Nat Commun"},{"key":"531_CR33","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s00018-007-7082-2","volume":"64","author":"MA Maynard","year":"2007","unstructured":"Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci. 2007;64:2170\u201380.","journal-title":"Cell Mol Life Sci"},{"key":"531_CR34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19:617\u201323.","journal-title":"Eur J Hum Genet"},{"key":"531_CR35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/ERC-10-0211","volume":"18","author":"G Eisenhofer","year":"2011","unstructured":"Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer. 2011;18:97\u2013111.","journal-title":"Endocr Relat Cancer"},{"key":"531_CR36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/1066896914537683","volume":"22","author":"P Santos","year":"2014","unstructured":"Santos P, Pimenta T, Taveira-Gomes A. Hereditary phaeochromocytoma. Int J Surg Pathol. 2014;22:393\u2013400.","journal-title":"Int J Surg Pathol"},{"key":"531_CR37","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-17-0523","volume":"178","author":"M Mannelli","year":"2018","unstructured":"Mannelli M, Canu L, Ercolino T, Rapizzi E, Martinelli S, Parenti G, et al. Diagnosis of endocrine disease: SDHx mutations: beyond pheochromocytomas and paragangliomas. Eur J Endocrinol. 2018;178:R11\u201317.","journal-title":"Eur J Endocrinol"},{"key":"531_CR38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","volume":"14","author":"LM Mulligan","year":"2014","unstructured":"Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14:173\u201386.","journal-title":"Nat Rev Cancer"},{"key":"531_CR39","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","volume":"86","author":"ML Brandi","year":"2001","unstructured":"Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR40","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","volume":"102","author":"CM Johannessen","year":"2005","unstructured":"Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA. 2005;102:8573\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"531_CR41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1530\/EJE-16-0233","volume":"175","author":"L K\u00e9p\u00e9n\u00e9kian","year":"2016","unstructured":"K\u00e9p\u00e9n\u00e9kian L, Mognetti T, Lifante JC, Giraudet AL, Houzard C, Pinson S, et al. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1. Eur J Endocrinol. 2016;175:335\u201344.","journal-title":"Eur J Endocrinol"},{"key":"531_CR42","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","volume":"18","author":"N Burnichon","year":"2012","unstructured":"Burnichon N, Casc\u00f3n A, Schiavi F, Morales NP, Comino-M\u00e9ndez I, Abermil N, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18:2828\u201337.","journal-title":"Clin Cancer Res"},{"key":"531_CR43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","volume":"42","author":"Y Qin","year":"2010","unstructured":"Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42:229\u201333.","journal-title":"Nat Genet"},{"key":"531_CR44","doi-asserted-by":"crossref","first-page":"E308","DOI":"10.1210\/jc.2014-2473","volume":"100","author":"SP Toledo","year":"2015","unstructured":"Toledo SP, Louren\u00e7o DM Jr, Sekiya T, Lucon AM, Baena ME, Castro CC, et al. Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation. J Clin Endocrinol Metab. 2015;100:E308\u201318.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR45","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","volume":"174","author":"PF Plouin","year":"2016","unstructured":"Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Guideline Working Group, et al. European Society of Endocrinology Clinical Practice Guideline for long-term followup of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174:G1\u201310.","journal-title":"Eur J Endocrinol"},{"key":"531_CR46","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","volume":"104","author":"A Buffet","year":"2019","unstructured":"Buffet A, Ben Aim L, Leboulleux S, Drui D, Vezzosi D, Lib\u00e9 R, French Group of Endocrine Tumors (GTE) and COMETE Network, et al. Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma. J Clin Endocrinol Metab. 2019;104:1109\u201318.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/1043-2760(93)90035-D","volume":"4","author":"WF Young Jr","year":"1993","unstructured":"Young WF Jr. Pheochromocytoma: 1926\u20131993. Trends Endocrinol Metab. 1993;4:122\u20137.","journal-title":"Trends Endocrinol Metab"},{"key":"531_CR48","first-page":"1480","volume":"86","author":"PF Plouin","year":"2001","unstructured":"Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001;86:1480\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR49","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","volume":"24","author":"V Strajina","year":"2017","unstructured":"Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ, Bible KC, et al. Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series. Ann Surg Oncol. 2017;24:1546\u201350.","journal-title":"Ann Surg Oncol"},{"key":"531_CR50","doi-asserted-by":"crossref","first-page":"E195","DOI":"10.3390\/cancers11020195","volume":"11","author":"J Kohlenberg","year":"2019","unstructured":"Kohlenberg J, Welch B, Hamidi O, Callstrom M, Morris J, Sprung J, et al. Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma. Cancers (Basel). 2019;11:E195.","journal-title":"Cancers (Basel)"},{"key":"531_CR51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","volume":"109","author":"SD Averbuch","year":"1988","unstructured":"Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109:267\u201373.","journal-title":"Ann Intern Med"},{"key":"531_CR52","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;81:642\u201351.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"531_CR53","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al. Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113:2020\u20138.","journal-title":"Cancer"},{"key":"531_CR54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer. 2013;4:103\u201310.","journal-title":"Horm Cancer."},{"key":"531_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijsu.2017.08.026","volume":"46","author":"JJ Butz","year":"2017","unstructured":"Butz JJ, Weingarten TN, Cavalcante AN, Bancos I, Young WF Jr, McKenzie TJ, et al. Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma. Int J Surg. 2017;46:1\u20136.","journal-title":"Int J Surg"},{"issue":"Suppl 3","key":"531_CR56","doi-asserted-by":"crossref","first-page":"S646","DOI":"10.1245\/s10434-015-4862-z","volume":"22","author":"H Wachtel","year":"2015","unstructured":"Wachtel H, Kennedy EH, Zaheer S, Bartlett EK, Fishbein L, Roses RE, et al. Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma. Ann Surg Oncol. 2015;22(Suppl 3):S646\u201354.","journal-title":"Ann Surg Oncol"},{"key":"531_CR57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131) I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80:487\u2013501.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"531_CR58","volume":"9","author":"H Wakabayashi","year":"2019","unstructured":"Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, et al. A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Sci Rep. 2019;9:7625.","journal-title":"Sci Rep."},{"key":"531_CR59","doi-asserted-by":"crossref","first-page":"E1018","DOI":"10.3390\/cancers11071018","volume":"11","author":"C Jimenez","year":"2019","unstructured":"Jimenez C, Erwin W, Chasen B. Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine. Cancers (Basel). 2019;11:E1018.","journal-title":"Cancers (Basel)"},{"key":"531_CR60","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60:623\u201330.","journal-title":"J Nucl Med"},{"key":"531_CR61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/cbr.2009.0695","volume":"25","author":"JA Barrett","year":"2010","unstructured":"Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, Kronauge JF, et al. Comparison of high-specific-activity ultratrace 123\/131I MIBG and carrier-added 123\/131I MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010;25:299\u2013308.","journal-title":"Cancer Biother Radiopharm"},{"key":"531_CR62","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","volume":"94","author":"C Jimenez","year":"2009","unstructured":"Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009;94:386\u201391.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR63","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O\u2019Kane","year":"2019","unstructured":"O\u2019Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer. 2019;120:1113\u20139.","journal-title":"Br J Cancer"},{"key":"531_CR64","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1677\/erc.1.01124","volume":"13","author":"DJ Gross","year":"2006","unstructured":"Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Israel Glivec in Solid Tumors Study Group, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13:535\u201340.","journal-title":"Endocr Relat Cancer"},{"key":"531_CR65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","volume":"57","author":"S Jasim","year":"2017","unstructured":"Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, et al. Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma. Endocrine. 2017;57:220\u20135.","journal-title":"Endocrine"},{"key":"531_CR66","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/en.2012-1854","volume":"154","author":"A Giubellino","year":"2013","unstructured":"Giubellino A, Bullova P, N\u00f6lting S, Turkova H, Powers JF, Liu Q, et al. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology. 2013;154:646\u201355.","journal-title":"Endocrinology"},{"key":"531_CR67","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","volume":"118","author":"DY Oh","year":"2012","unstructured":"Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas. Cancer. 2012;118:6162\u201370.","journal-title":"Cancer"},{"key":"531_CR68","doi-asserted-by":"crossref","first-page":"e000347","DOI":"10.1136\/jitc-2019-000347","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon AJ, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020;8:e000347.","journal-title":"J Immunother Cancer"},{"key":"531_CR69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","volume":"3","author":"W Breen","year":"2017","unstructured":"Breen W, Bancos I, Young WF Jr, Bible KC, Laack NN, Foote RL, et al. External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol. 2017;3:25\u201329.","journal-title":"Adv Radiat Oncol"},{"key":"531_CR70","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","volume":"98","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013;98:1492\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1507\/endocrj.43.511","volume":"43","author":"S Teno","year":"1996","unstructured":"Teno S, Tanabe A, Nomura K, Demura H. Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic pheochromocytoma. Endocr J. 1996;43:511\u20136.","journal-title":"Endocr J"},{"key":"531_CR72","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97:4040\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"531_CR73","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.13995.1","volume":"7","author":"R Toledo","year":"2018","unstructured":"Toledo R, Jimenez C. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. F1000Res. 2018;7:F1000.","journal-title":"F1000Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-0531-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-0531-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-0531-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T13:40:58Z","timestamp":1667742058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-0531-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["531"],"URL":"https:\/\/doi.org\/10.1038\/s41440-020-0531-0","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}